Compare Noble Corporation plc (NE) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs Vertex Pharmaceuticals Incorporated — how do they compare? Noble Corporation plc trades at $45.83 (market cap $7.33B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 18.3× Noble Corporation plc's market cap, and Noble Corporation plc pays a 4.36% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| NE | VRTX | |
|---|---|---|
Market Cap | $7.33B | $134.06B |
Sector | Technology | Health |
52-Week High | $54.37 | $557.96 |
52-Week Low | $26.70 | $376.62 |
Enterprise Value | $8.76B | $128.18B |
Dividend Yield | 4.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Noble Corporation (NE) trades at $45.89, up 0.61% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $46.00. Recent earnings show mixed quarterly results, with a Q1 2026 beat but Q2 and Q4 2025 misses, while annual revenue declined to $3.1 billion in 2026 from $3.3 billion in 2025, and net income fell to $150 million. The company maintains positive cash flow from operations and announced a $0.50 dividend payable in September 2026.
Outlook is cautious due to earnings volatility and revenue contraction, offset by strong cash generation and analyst support. Key risks include ongoing legal investigations and competitive pressures in the offshore drilling sector. The stock presents a balanced opportunity with moderate upside to the price target, but investors should monitor earnings consistency and legal developments.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
